Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human Oncostatin M (OSM) protein, 50µg  

ActiveMax® Recombinant Human Oncostatin M (OSM) protein, 50µg

ActiveMax® Recombinant Human Oncostatin M (OSM) Ala 26 - Arg 252 was produced in human 293 cells (HEK293), Tag free

Synonym: Recombinant Human Protein, OSM,MGC20461,Oncostatin M

More details

OSM-H5213-50

Availability: within 7 days

540,00 €

Background
Oncostatin M is also known as OSM, is a glycoprotein belonging to the interleukin-6 family of cytokines that has functions mainly in cell growth. Of these cytokines it most closely resembles leukemia inhibitory factor (LIF) in both structure and function. However, it is as yet poorly defined and is proving important in liver development, haematopoeisis, inflammation and possibly CNS development. It is also associated with bone formation and destruction. OSM signals through cell surface receptors that contain the protein gp130. The type I receptor is composed of gp130 and LIFR, the type II receptor is composed of gp130 and OSMR. Oncostatin M (OSM) was previoustly identified by its ability to inhibit the growth of cells from melanoma and other solid tumors. It also has been reported that OSM, like LIF, IL-6 and G-CSF, has the ability to inhibit the proliferation of murine M1 myeloid leukemic cells and can induce their differentiation into macrophage-like cells. The human form of OSM is insensitive between pH2 and 11 and resistant to heating for one hour at 56 degree but is not stable at 90 degrees. The three dimensional structure of human OSM has been solved to atomic resolution, confirming the predicted long chain four helix bundle topology. Comparing this structure with the known structures of other known LC cytokines shows it to be most closely related to LIF.

Source
ActiveMax® Recombinant Human Oncostatin M, Tag Free (OSM-H5213) is expressed from human 293 cells (HEK293). It contains AA Ala 26 - Arg 252 (Accession # NP_065391.1).
Predicted N-terminus: Ala 26

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 25.8 kDa. The protein migrates as 36 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the ActiveMax® Human Oncostatin M by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Oncostatin M Cytokine Associated With Chronic Itch"
Suran
JAMA (2022) 327 (4), 313
(2) "Enhanced effect of recombinant adenoviruses co-expression of ING4 and OSM on anti-tumour activity of laryngeal cancer"
Cheng, Zhao, Li et al
J Cell Mol Med (2022)
(3) "High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists"
Guo, Ross, Chande et al
Sci Rep (2022) 12 (1), 1185
Showing 1-3 of 1996 papers.